News
Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
Hot topic
REGULATION
China to Enforce Revised Rules on Drug Patent Term Compensation
The revised Rules on the Implementation of the Patent Law of the People’s Republic of China is set to come into effect on January 20, 2024. The revised Rules includes provisions specifically related to drug patents which are significant for new drug applicants.
Jan 19, 2024
INDUSTRY
POLICY
China Starts Implementing the 2023 National Reimbursement Drug List (NRDL)
On Dec 13, 2023, China published the 2023 National Reimbursement Drug List (NRDL), which is set to take effect on the first day of 2024. The updated 2023 NRDL includes a total of 3,088 drugs, with 126 new additions and the removal of one drug, Elbasvir and Grazoprevir Tablets.
Jan 01, 2024
PIPELINE
Chinese Antibody-drug Conjugates (ADCs) Licensed Overseas Exceeds $23 Billion This Year
On Dec 20, 2023, Hansoh Pharma, a Chinese biopharma company, announced that it had reached an exclusive deal with GSK for HS-20093, an antibody-drug conjugate (ADC) targeting B7-H3. This deal is one of 15 cross-border licensing deals inked this year between Chinese ADC-focused companies and multinational corporations this year.
Dec 21, 2023
Most Popular
- [Updated] Pharma Licensing Deals Involving Chinese Companies in 2023
- [Updated] Top 10 CROs With the Highest Revenues in 2023
- Decoding China's Good Pharmacovigilance Practices (GVP)
- 2023 China CDE Drug Evaluation Report
- [Updated] China Expedites Process for Transferring Overseas Drug Manufacturing Sites to China